THERAPY DOSSIER · th-4030af9add7a

COA-Cl, a novel synthesised adenosine analogue

Drug · No confident ChEMBL match; COA-Cl (2Cl-C.OXT-A) is a preclinical synthetic adenosine/nucleoside analogue reported as an S1P1/adenosine-pathway angiogenic agent. No ClinicalTrials.gov record.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No confident ChEMBL match; COA-Cl (2Cl-C.OXT-A) is a preclinical synthetic adenosine/nucleoside analogue reported as an S1P1/adenosine-pathway angiogenic agent. No ClinicalTrials.gov record.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33316301 ↗2020Mixed findings

The protective effect and mechanism of COA-Cl in acute phase after spinal cord injury.

RatSpinal cord injuryContusionSprague-Dawley6 mg/kgAcute group dosed immediately after injury; subacute group dosed from 4 days af…

Model: Contusion spinal cord injury at the T9 vertebra produced with a weight-drop device

COA-Cl given immediately after injury significantly improved BBB score and inclined plane performance and significantly reduced cavity volume and apoptosis, with increased pERK/ERK at 7 days, whereas administration beginning 4 days after injury produced no significant motor improvement, indicating…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…